Targeted therapies for patients with germ cell tumors
- 25 March 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 17 (4), 511-522
- https://doi.org/10.1517/13543784.17.4.511
Abstract
Patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy but the outcome remains unsatisfactory for patients with relapsed disease. Targeted therapies have changed the standard of care for many advanced solid tumors. To identify clinically available drugs that have the potential as targeted therapies in germ cell tumors. A literature search was carried out for expression and mutation status of receptor tyrosine kinases in germ cell tumors, also a literature and clinical trial database search for completed and ongoing clinical trials with targeted therapies in germ cell tumors. c-KIT is mutated in some seminomas and bilateral germ cell tumors. Several case reports and small clinical trials with trastuzumab, thalidomide and imatinib were identified and clinical trials with sunitinib and bevacizumab are ongoing. We expect an increased use of targeted therapies in advanced germ cell tumors in the next few years.Keywords
This publication has 100 references indexed in Scilit:
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Testicular germ-cell tumours in a broader perspectiveNature Reviews Cancer, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumorsOncogene, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998